Predictive value of serum interleukin-33 and thymic stromal lymphopoietin for the risk of acute exacerbation in patients with chronic obstructive pulmonary disease.
{"title":"Predictive value of serum interleukin-33 and thymic stromal lymphopoietin for the risk of acute exacerbation in patients with chronic obstructive pulmonary disease.","authors":"Shijia Yin, Kang Xu, Shi Wu, Hua Liu, Zhen Ding","doi":"10.3389/fmed.2025.1592734","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) lacks reliable biomarkers. This study aimed to explore the predictive value of serum interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) for acute exacerbations of COPD (AECOPD).</p><p><strong>Methods: </strong>This retrospective study included patients with stable-phase COPD between June 2023 and June 2024 at the Third Affiliated Hospital of Anhui Medical University. Patients were assigned to the low-risk and high-risk groups according to the number and severity of AECOPD events. Multivariable logistic regression analysis was used to identify the factors of AECOPD risk. Receiver operating characteristic (ROC) curves were used to assess the predictive value of IL-33 and TSLP for AECOPD risk.</p><p><strong>Results: </strong>A total of 76 patients were enrolled, with 33 in the low-risk group and 43 in the high-risk group. Serum IL-33 (835.30 vs. 770.30, <i>p</i> = 0.008) and TSLP (102.20 vs. 90.45, <i>p</i> < 0.001) levels were higher in the high-risk group than in the low-risk group. Serum TSLP (odds ratio (OR) = 1.095, 95% confidence interval (CI): 1.013-1.184, <i>p</i> = 0.022) was independently associated with AECOPD. The area under the curve (AUC) for IL-33 in predicting AE was 0.677 (95%CI: 0.554-0.801), with 93.0% sensitivity and 39.4% specificity. The AUC for TSLP was 0.768 (95%CI: 0.659-0.878), with 76.7% sensitivity and 72.7% specificity. Combined prediction using IL-33 and TSLP yielded an AUC of 0.779 (95%CI: 0.669-0.888), with 81.4% sensitivity and 72.7% specificity.</p><p><strong>Conclusion: </strong>High serum TSLP might be associated with an increased risk of AECOPD. While IL-33 alone showed high sensitivity and low specificity, its potential predictive value may be worth exploring.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1592734"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488408/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1592734","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) lacks reliable biomarkers. This study aimed to explore the predictive value of serum interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) for acute exacerbations of COPD (AECOPD).
Methods: This retrospective study included patients with stable-phase COPD between June 2023 and June 2024 at the Third Affiliated Hospital of Anhui Medical University. Patients were assigned to the low-risk and high-risk groups according to the number and severity of AECOPD events. Multivariable logistic regression analysis was used to identify the factors of AECOPD risk. Receiver operating characteristic (ROC) curves were used to assess the predictive value of IL-33 and TSLP for AECOPD risk.
Results: A total of 76 patients were enrolled, with 33 in the low-risk group and 43 in the high-risk group. Serum IL-33 (835.30 vs. 770.30, p = 0.008) and TSLP (102.20 vs. 90.45, p < 0.001) levels were higher in the high-risk group than in the low-risk group. Serum TSLP (odds ratio (OR) = 1.095, 95% confidence interval (CI): 1.013-1.184, p = 0.022) was independently associated with AECOPD. The area under the curve (AUC) for IL-33 in predicting AE was 0.677 (95%CI: 0.554-0.801), with 93.0% sensitivity and 39.4% specificity. The AUC for TSLP was 0.768 (95%CI: 0.659-0.878), with 76.7% sensitivity and 72.7% specificity. Combined prediction using IL-33 and TSLP yielded an AUC of 0.779 (95%CI: 0.669-0.888), with 81.4% sensitivity and 72.7% specificity.
Conclusion: High serum TSLP might be associated with an increased risk of AECOPD. While IL-33 alone showed high sensitivity and low specificity, its potential predictive value may be worth exploring.
背景：慢性阻塞性肺疾病（COPD）患者急性加重缺乏可靠的生物标志物。本研究旨在探讨血清白细胞介素-33 （IL-33）和胸腺基质淋巴生成素（TSLP）对慢性阻塞性肺疾病急性加重期（AECOPD）的预测价值。方法：本回顾性研究纳入了2023年6月至2024年6月在安徽医科大学第三附属医院就诊的稳定期COPD患者。根据AECOPD事件的数量和严重程度将患者分为低危组和高危组。采用多变量logistic回归分析确定AECOPD危险因素。采用受试者工作特征（ROC）曲线评价IL-33和TSLP对AECOPD风险的预测价值。结果：共纳入76例患者，其中低危组33例，高危组43例。血清IL-33 （835.30 vs. 770.30, p = 0.008）和TSLP （102.20 vs. 90.45, p p = 0.022）与AECOPD独立相关。IL-33预测AE的曲线下面积（AUC）为0.677 (95%CI: 0.554 ~ 0.801)，敏感性93.0%，特异性39.4%。TSLP的AUC为0.768 (95%CI: 0.659-0.878)，敏感性76.7%，特异性72.7%。IL-33和TSLP联合预测的AUC为0.779 (95%CI: 0.669-0.888)，敏感性为81.4%，特异性为72.7%。结论：血清TSLP增高可能与AECOPD发病风险增加有关。虽然单独使用IL-33敏感性高，特异性低，但其潜在的预测价值值得探讨。
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
